DOCSLIB.ORG

Product Pharmacology and Medical Actives in Achieving Therapeutic Benefits

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Product Pharmacology and Medical Actives in Achieving Therapeutic Benefits Product Pharmacology and Medical Actives in Achieving Therapeutic Benefits James R. Schwartz Beauty Care Product Development, The Procter & Gamble Company, Cincinnati, Ohio, USA J Investig Dermatol Symp Proc 10:198 –200, 2005 Scalp skin is physiologically very similar to non-palmoplan- at least as strong a determinant of in-use activity as the tar skin of the rest of the body, except for the very high intrinsic active potency. For example, a comparison of clin- concentration of sebaceous glands (Giacometti, 1965). The ical flake-reduction efficacy of a variety 1% PTZ-based D/ scalp environment, however, is much different in being cov- SD shampoo products demonstrates a wide range of mag- ered by a thick fabric of hair. There are about 250 hair fibers nitude of therapeutic benefits. Much of this variation is likely per cm2, which results, for a typical individual, in a hair sur- due to the varying efficiency of delivery of PTZ, a particulate face area of 50,000 cm2 relative to the scalp surface area of active, to the scalp surface. Particulate PTZ delivery will be 600 cm2. Together, these parameters indicate the relative affected by the physical size and shape of the particle (as inaccessibility of the scalp surface to targeted delivery of well as other formulation parameters, which will not be cov- actives; relatively low delivery efficiency in this protected ered further here). Particles which are flat cover the scalp environment is an inherent challenge to achieving thera- surface more efficiently than those that are not. The particle peutic benefits. This is especially true of the most patient- size is also critical as smaller particles provide better surface friendly format—shampoos—since a rinsing step is involved coverage but are more difficult to retain on the scalp after and the product cannot interfere with achieving desired rinsing. These two opposing factors result in an optimum hair cosmetic benefits (compliance decreases dramatically size to maximize active delivery. Shampoo product formu- if hair cosmetics are poor). This places a large demand on lations utilizing PTZ particles optimized for delivery outper- actives with high activity since delivery efficiency will be form those utilizing standard forms of the active (Fig 1). This inherently low as well as development of product phar- exemplifies one variable, beyond active potency, that must macologies that maximize the benefit of the actives em- be considered in selecting a therapeutic treatment. ployed. This situation will be exemplified for the most Another important pharmacological variable that must be common scalp care therapeutic products, those designed considered is the role of the ‘‘non-functional’’ excipients in to treat dandruff and seborrheic dermatitis (D/SD) utilizing anti-fungal actives to reduce Malassezia content on the scalp. The most common anti-fungal materials used in D/SD scalp therapies include those based on rational chemical design principles (ketoconazole, climbazole, pyrithione zinc (PTZ), piroctone olamine and ciclopirox olamine) as well as materials originating from indeterminate histories (selenium sulfide, sulfur, coal tar, and salicylic acid). Because of the aforementioned demands on activity due to challenging delivery, only those materials with high intrinsic anti-fungal activity should be considered as the basis for therapeutic products. Based on measurement of minimal inhibitory concentrations (MIC) against Malassezia, the most potent materials from this group are pyrithione zinc, selenium sulfide, climbazole, and ketoconazole (VanGerven and Odds, 1995; Schmid and Ru¨ hl-Ho¨ rster, 1996). For a formulated therapeutic product to be effective, a Figure 1 potent active is a necessary but insufficient condition to The impact of pyrithione zinc (PTZ) particle size on clinically ob- achieve activity. The way the active is delivered to the scalp served anti-dandruff efficacy from shampoo matrices. Sub-micron from the product formula, i.e., the product pharmacology, is particles are difficult to retain on the scalp after rinsing, whereas the distribution of particles on the surface of the scalp (inset) improves as the particles become smaller (note fungal cell target drawn to scale). These off-setting factors result in an optimum particle size for efficacy Abbreviation: PTZ, pyrithione zinc of 2.5 mm. Copyright r 2005 by The Society for Investigative Dermatology, Inc. 198 10 : 3 DECEMBER 2005 PRODUCT PHARMACOLOGY AND THERAPEUTIC BENEFITS 199 Figure 2 A summary of relevant pyrithione zinc (PTZ) equilibria governing realization of anti-fungal activity. (A) PTZ particles yield a soluble portion of PTZ molecules, which penetrate the fungal cell membrane (green). (B) PTZ undergoes dissociative equilibria, which reduce the portion of the material present in the bio-active complexed form. (C) The addition of an exogenous source of zinc ions (red) shifts the equilibria in the favor of the complexed PTZ form, thereby increasing delivery to the fungal cells (red). the product formulation–it is well known that they can mod- 100 times more effective than, e.g., the iron salt (MIC of 500 ulate, either positively or negatively, the activity of the drug ppm). This clearly highlights the importance of zinc to the active. A specific example of how product excipients can activity of PTZ and establishes the intact PTZ material as affect the activity of a scalp care formula is the addition of the anti-fungal bio-active species. This conclusion becomes zinc materials to PTZ-based therapeutic products. To un- the basis for understanding the effect of the formulation derstand the mechanism behind this effect requires some containing a zinc excipient on the activity of PTZ. understanding of a key component of the anti-fungal mech- PTZ, like all metal-organic complexes when in a liquid anism of the active ingredient PTZ itself. medium, is governed by an equilibrium between the asso- Although the detailed understanding of the biological ciated zinc-pyrithione complex (i.e., PTZ) and dissociated mechanism of PTZ is beyond the scope of the article, it is zinc and pyrithione components (Seymour and Bailey, important to highlight the importance of the zinc component 1981). Since PTZ is the bio-active species, dissociation of the metal-organic complex PTZ. PTZ is based on the has negative consequences on efficacy. The greater the organic entity pyrithione (PT) where zinc ion ( þ 2) forms a dissociation, the less PTZ is present in the medium in a form salt with PT (À1) in a 1:2 ratio. Evaluation of the in vitro anti- leading to anti-fungal activity. This is represented in the fungal activity of the organic component (sodium pyrithione) equilibria summarized in Fig 2. as well as a number of metal salts of this material (including Zinc ion has essentially no anti-fungal activity of its own, zinc, iron, nickel, and copper), demonstrates a range of over but enhances the anti-fungal activity of PTZ by over an or- three orders of magnitude (1000-fold) of potency. The zinc der of magnitude in in vitro evaluations (Fig 3). The mech- salt (MIC of 8 ppm) is almost 10 times more potent than anism involves shifting the equilibrium between PTZ and its sodium pyrithione (MIC of 64 ppm) alone and approximately dissociated components. The basis for this effect is the 200 SCHWARTZ JID SYMPOSIUM PROCEEDINGS on increasing the bio-availability of PTZ as the equilibria in Fig 2C demonstrate. The zinc-enhanced PTZ activity observed in vitro and understood in terms of increased bio-availability results in increased performance in vivo in complex matrices as well. Quantitation of in vivo Malassezia reduction from shampoo matrices demonstrates PTZ formulation with zinc to be more effective than PTZ formulations alone. This benefit also translates to significantly improved clinical flake re- duction from shampoos containing added zinc as an ex- cipient. In summary, whereas potent scalp actives must be se- lected to achieve therapeutic activity, the product pharma- cology must be considered in both the design and selection of the product. Utilizing the example of PTZ-based D/SD treatments, wide variability in clinical performance has been observed. The origins can be understood in terms of how efficiently the product delivers the active to the scalp surface Figure 3 as well as the role that excipients play on modulating activity Kill rate microbiology evaluation of shampoo prototypes contain- of the product formulation containing the drug active. ing no active (placebo), pyrithione zinc (PTZ) alone, added zinc alone and the combination. Zinc alone has no activity, but it potenti- ates the activity of the PTZ formula. This work was funded by the Procter & Gamble Company. The author wishes to acknowledge David Kaufman for microbiological assess- ments and Durk Domaschko and Matt Chestnut for visualization of well-established principle in chemical equilibria called intracellular zinc delivery. LeChaˆ telier’s Principle. Briefly, it states that a change im- DOI: 10.1111/j.1087-0024.2005.10105.x posed on a system at equilibrium shifts the equilibrium in a way that reduces the effect of the change. In practical Manuscript received September 20, 2004; revised November 23, 2004; accepted for publication December 2, 2004 terms, this means that the addition of a material which ap- pears on one side of the equilibrium shifts the equilibrium in Address correspondence to: James R. Schwartz, PhD, The Procter & the opposite direction. In the case of the PTZ equilibria, Gamble Company, 11511 Reed Hartman Hwy, Cincinnati, OH 45241, added zinc forces the equilibrium towards the bio-active USA. Email: [email protected] PTZ complex. In effect, additional zinc is acting in the for- mula to increase the bio-availability of PTZ to exert its anti- fungal activity and is therefore considered a potentiated References PTZ formula. Giacometti L: The anatomy of the human scalp. Adv Biol Skin 6:107–120, 1965 Support for the mechanism comes from quantitation of Kim CH, Kim JH, Moon SJ, et al: Pyrithione, a zinc ionophore, inhibits NF-kB PTZ penetration into model mammalian cells.
Load more

Recommended publications
  • A Comparison of Clinical Efficacy Between a Basic Shampoo With
    Original Article A Comparison of Clinical Efficacy between a Basic Shampoo with Herbal Extracts Containing Climbazole and Its Similar Sample Containing Piroctone Olamine in the Treatment of Dandruff and Seborrheic Dermatitis Hosein Rastegar, PhD1 Abstract Hamidreza Ahmadi Ashtiani, PhD Background: Dandruff especially with itching and inflammation is a Student2 common complaint among patients in the clinic and its treatment is Mohammad Baghaei, Pharm D3 much challenging. Chemical anti fungal substances used in Saeid Bokaei, PhD4 antidandruff shampoos are common treatments. The aim of this study 5 was to compare the clinical efficacy of two of these anti dandruff Amirhoushang Ehsani, MD substances, climbazole and piroctone olamine in the treatment of Pedram Noormohammadpour, MD5 dandruff and seborrheic dermatitis in shampoos with herbal extracts. 5 Sahar Azizahari, MD Methods: One hundred and twenty men with scalp dandruff of the Ramin Khanmohammad6 same severity, between 20-30 years old and in the same occupational condition in terms of sun exposure or environmental 1. Laboratory Research Centre of Food and pollution were selected and divided randomly into two 60-subject Drug, Ministry of Health and Medical groups. After each shampoo was applied 3 times a week for 5 Educations, Islamic Republic of Iran weeks one in group 1 and the other in group 2, patients were 2. Department of Clinical Biochemistry, assessed for existence of itching and redness of scalp and reduction School of Medical Science, Tarbiat-e- in dandruff and results were compared between two groups. Modarres University, Tehran, Iran and Biochemistry & Nutrition Department of Results: Itching and redness were completely cured in both groups Zanjan Medical University and Institute of after treatment.
    [Show full text]
  • Results of Monitoring and Guidance Based on the Imported Foods Monitoring and Guidance Plan for FY2007
    Contact Office of Imported Food Safety, Inspection and Safety Division, Department of Food Safety, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare (extension: 2474, 2497, 2498) Results of Monitoring and Guidance Based on the Imported Foods Monitoring and Guidance Plan for FY2007 August 2008 Department of Food Safety Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare Results of Monitoring and Guidance Based on the Imported Foods Monitoring and Guidance Plan for FY2007 Introduction The total number of foods, additives, equipment, containers and packages, and toys (hereinafter collectively referred to as “foods”) imported to Japan in FY2007 was about 1.80 million, with an imported weight of about 32.3 million tons. According to the Food Balance Sheet for FY 2007 by the Ministry of Agriculture, Forestry and Fisheries, the food self-sufficiency ratio in Japan (food self-sufficiency ratio based on the total caloric value supplied) was estimated at 40%, indicating that, on a calorie basis, approximately 60% of foods consumed in Japan are imported. Regarding the monitoring and guidance conducted by the national government for the purpose of ensuring the safety of foods imported to Japan (hereinafter referred to as “imported foods”), the Imported Foods Monitoring and Guidance Plan for FY2007 (hereinafter referred to as the “Plan”) was developed based on public comments and risk communications, and was conduced in line with the Guidelines for the Implementation of Monitoring and Guidance on Food Sanitation (Notification No. 301 of the Ministry of Labour, Health and Welfare, 2003) under Article 23, paragraph 1 of the Food Sanitation Law (Law No.
    [Show full text]
  • Development and Validation of UV Spectroscopic Method for Estimation of Climbazole in Climbazole Shampoo
    RESEARCH ARTICLE Am. J. PharmTech Res. 2020; 10(01) ISSN: 2249-3387 Journal home page: http://www.ajptr.com/ Development and Validation of UV Spectroscopic Method for Estimation of Climbazole in Climbazole Shampoo Rajashree N. Patil*1, Pratiksha A. Patil1, Swapnil R. Patil2, Amol Sawale2 1.Department of Pharmaceutical Chemistry, Arunamai College of Pharmacy, Mamurabad, North Maharashtra University, Jalgaon (MH) INDIA 425002. 2.Department of Pharmaceutics and Quality Assurance, Vidya Bharati College of Pharmacy, Amravati University, Amravati (MH) INDIA 444602. ABSTRACT To develop and validate simple, rapid, linear, accurate, precise and economical UV Spectroscopic method for estimation of Climbazole in Climbazole shampoo. The drug is freely soluble in organic solvents such as Chloroform and Methanol. The drug was identified in terms of solubility studies and on the basis of melting point done on Melting Point Apparatus of Equiptronics. It showed absorption maxima were determined in Methanol: Water (50:50). The drug obeyed the Beer’s law and showed good correlation of concentration with absorption which reflect in linearity. The UV spectroscopic method was developed for estimation of Climbazole in shampoo dosage form and also validated as per ICH guidelines. The drug is freely soluble in organic solvents such as Methanol, Chloroform. So, the Analytical Grade Methanol: Water is used as a diluent in equal proportion for method. The melting point of Climbazole was found to be 93-94˚C (uncorrected). It showed absorption maxima 256 nm in Methanol: Water (50:50). On the basis of absorption spectrum the working concentration was set on 6µg/ml (PPM). The linearity was observed between 2-10 μg/ml (PPM).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,911,795 B2 Schmaus Et Al
    US00891. 1795B2 (12) United States Patent (10) Patent No.: US 8,911,795 B2 Schmaus et al. (45) Date of Patent: *Dec. 16, 2014 (54) COMPOSITIONS COMPRISING (52) U.S. Cl. DHYDROAVENANTHRAMIDED AND CPC ............. A61O5/006 (2013.01); A61 K 2800/75 CLIMBAZOLEAS COSMETIC AND (2013.01); A61 K31/196 (2013.01); A61 K PHARMACEUTICAL COMPOSITIONS FOR 8/445 (2013.01); A61O 19/00 (2013.01) ALLEVIATING ITCHING USPC ............ 424/640; 514/188: 514/345; 514/563 (58) Field of Classification Search (75) Inventors: Gerhard Schmaus, Höxter (DE); None Joachim Röding, Badenweiler (DE) See application file for complete search history. (73) Assignee: Symrise AG, Holzminden (DE) (56) References Cited U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 4,070,484 A 1/1978 Harita et al. 8,409,552 B2 * 4/2013 Schmaus et al. ................ 424,61 U.S.C. 154(b) by 1390 days. 2003/0161802 A1* 8, 2003 Flammer et al. ............. 424.70.1 This patent is Subject to a terminal dis 2003/0228272 Al 12/2003 Amjad et al. claimer. 2006/0089413 A1* 4/2006 Schmaus et al. .............. 514,563 (21) Appl. No.: 12/095,453 FOREIGN PATENT DOCUMENTS JP 2005187398 7/2005 (22) PCT Filed: Nov. 3, 2006 WO WO-2004O35O15 4/2004 WO WO 2004/047833 * 6, 2004 ........... A61K 31,196 (86). PCT No.: PCT/EP2006/068077 WO WO-2004O47833 6, 2004 WO WO-2006134013 12/2006 S371 (c)(1), WO WO-2006134120 12/2006 (2), (4) Date: Apr. 23, 2009 OTHER PUBLICATIONS (87) PCT Pub.
    [Show full text]
  • Climbazole Is a New Potent Inducer of Rat Hepatic Cytochrome P450
    The Journal of Toxicological Sciences, 141 Vol.26, No.3, 141―150, 2001 CLIMBAZOLE IS A NEW POTENT INDUCER OF RAT HEPATIC CYTOCHROME P450 Yasuna KOBAYASHI1, Michiya SUZUKI2, Naomi OHSHIRO1, Takashi SUNAGAWA2, Tadanori SASAKI1, Shogo TOKUYAMA1, Toshinori YAMAMOTO1 and Takemi YOSHIDA2 1Departments of Clinical Pharmacy and 2Biochemical Toxicology, School of Pharmaceutical Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo142-8555, Japan (Received March 19, 2001; Accepted April 25, 2001) ABSTRACT ― We examined the effect of climbazole on the induction of rat hepatic microsomal cytochrome P450 (P450), and compared the induction potency with other N-substituted azole drugs such as clorimazole. We found that climbazole is found to be a potent inducer of rat hepatic microsomal P450 as clorimazole. Induced level of P450 by climbazole was almost similar in extent to clorimazole when compared with other imidazole drugs in a dose- and time-dependent manner. Parallel to the increase in P450, climbazole increased aminopyrine and erythromycin N-demethylase, ethoxycoumarin O-deethylase, and androstenedione 16β- and 15α/6βhydroxylase activities; however, clorimazole did not induce aminopyrine N-demethylase activity irrespective of its marked increase in P450 content. Immunoblot analyses revealed that climbazole induced CYP2B1, 3A2 and 4A1. The present findings indicate that climbazole is a new potent inducer of hepatic microsomal P450 and drug-metabolizing enzymes like clori- mazole, but it may have some differential mechanism(s) for these enzymes’ induction in rat liver. KEY WORDS: Climbazole, Cytochrome P450, Imidazole, Enzyme induction INTRODUCTION ducing P450 induction. Additionally, we have shown that 1-trityl- and 1-diphenylmethyl-imidazoles induces Cytochrome P450 (P450) constitutes a superfami- CYP2B, whereas 1-benzylimidazole increases both ly of hemeproteins that play a pivotal role in the metab- CYP2B and CYP1A species (Kobayashi et al., 1993).
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,834,409 Ramachandran Et Al
    USOO5834.409A United States Patent (19) 11 Patent Number: 5,834,409 Ramachandran et al. (45) Date of Patent: *Nov. 10, 1998 54 SCALP CARE PRODUCTS CONTAINING 4,867,971 9/1989 Ryan et al. ............................... 424/81 ANTI ITCHING/ANTI IRRITANT AGENTS 4.885,107 12/1989 Wetzel ... 252/106 4,895,727 1/1990 Allen ... ... 424/642 (75) Inventors: Pallassana Narayanier 4,921,170 5/1990 Grollier ................................... 239/304 4,925,659 5/1990 Grollier et al. ........................... 424/78 Ramachandran, Robbinsville; 4997,641 3/1991 Hartnett et al. ... 424/70 Clarence Ralph Robbins, Martinsville; 4,999,195 3/1991 Hayes.............. ... 424/114 Amrit Manilal Patel, Dayton, all of 5,002,761 3/1991 Mueller et al. ... 424/70 N.J. 5,051,250 9/1991 Patel et al. ... ... 424/70 5,091,171 2/1992 Yu et al. ......... 424/642 73) Assignee: Colgate-Palmolive Company, New 5,100,658 3/1992 Bolich, Jr. et al. ... 424/70 York, N.Y. 5,104,646 4/1992 Bolich, Jr. et al. ..... ... 424/70 5,106,609 4/1992 Bolich, Jr. et al. ... 424/70 Notice: This patent issued on a continued pros 5,106,613 4/1992 Hartnett et al. ........................... 424/71 ecution application filed under 37 CFR 5,151,209 9/1992 McCall et al... 252/174.15 1.53(d), and is subject to the twenty year 5,213,716 5/1993 Patel et al. .............................. 252/547 patent term provisions of 35 U.S.C. 5,346,642 9/1994 Patel et al. 252/174.21 5,348,736 9/1994 Patel .........................................
    [Show full text]
  • Topical Antifungals Used for Treatment of Seborrheic Dermatitis
    Journal of Bacteriology & Mycology: Open Access Review Article Open Access Topical antifungals used for treatment of seborrheic dermatitis Abstract Volume 4 Issue 1 - 2017 Seborrheic dermatitis is a common inflammatory condition mainly affecting scalp, Sundeep Chowdhry, Shikha Gupta, Paschal face and other seborrheic sites, characterized by a chronic relapsing course. The mainstay of treatment includes topical therapy comprising antifungals (ketoconazole, D’souza Department of Dermatology, ESI PGIMSR, India ciclopirox olamine) and anti-inflammatory agents along with providing symptomatic relief from itching. Oral antifungals and retinoids are indicated only in the severe, Correspondence: Sundeep Chowdhry, Senior Specialist and recalcitrant cases. The objective of this review is to discuss various topical antifungals Assistant Professor, Department of Dermatology, ESI PGIMSR, available for use in seborrheic dermatitis of scalp, face and flexural areas, discuss their Basaidarapur, New Delhi, India, Tel 919910084482, efficacy and safety profiles from relevant studies available in the literature along with Email [email protected] upcoming novel delivery methods to enhance the efficacy of these drugs. Received: October 28, 2016 | Published: January 06, 2017 Keywords: seborrheic dermatitis, antifungal agents, ketoconazole, ciclopirox Introduction Discussion Seborrheic dermatitis (SD) is a common, chronic inflammatory Treatment considerations disease that affects around 1-3% of the general population in many countries including the U.S., 3-5% of patients consisting of young Treatment for SD should aim for not just achieving remission of adults. The incidence of the disease has two peaks: one in newborn lesions but also to eliminate itching and burning sensation and prevent 6 infants up to three months of age, and the other in adults of around recurrence of the disease.
    [Show full text]
  • Topical Delivery of Climbazole to Mammalian Skin T ⁎ Miguel Paz-Alvareza, , Paul D.A
    International Journal of Pharmaceutics 549 (2018) 317–324 Contents lists available at ScienceDirect International Journal of Pharmaceutics journal homepage: www.elsevier.com/locate/ijpharm Topical delivery of climbazole to mammalian skin T ⁎ Miguel Paz-Alvareza, , Paul D.A. Pudneyb, Jonathan Hadgrafta, Majella E. Lanea a UCL School of Pharmacy, 29-39 Brunswick Square, WC1N 1AX London, UK b Strategic Science Group, Unilever R&D, Colworth Science Park, MK44 1LQ, Sharnbrook, Bedford, UK ARTICLE INFO ABSTRACT Keywords: Dandruff is a common condition, affecting up to half the global population of immunocompetent adults at some In vitro time during their lives and it has been highly correlated with the over-expression of the fungus Malassezia spp. Porcine skin Climbazole (CBZ) is used as an antifungal and preservative agent in many marketed formulations for the Human skin treatment of dandruff. While the efficacy of CBZ in vitro and in vivo has previously been reported, limited in- Finite dose formation has been published about the uptake and deposition of CBZ in the skin. Hence, our aim was to Infinite dose investigate the skin permeation of CBZ as well as the influence of various solvents on CBZ skin delivery. Four Climbazole solvents were selected for the permeability studies of CBZ, namely propylene glycol (PG), octyl salicylate (OSal), Transcutol® P (TC) and polyethylene glycol 200 (PEG). The criteria for selection were based on their wide use as excipients in commercial formulations, their potential to act as skin penetration enhancers and their favourable safety profiles. 1% (w/v) solutions of CBZ were applied under infinite and finite dose conditions using Franz type diffusion cells to human and porcine skin.
    [Show full text]
  • Open Access Article Under the CC by License (
    Molecular and Cellular Endocrinology 524 (2021) 111168 Contents lists available at ScienceDirect Molecular and Cellular Endocrinology journal homepage: www.elsevier.com/locate/mce Antifungal therapy with azoles and the syndrome of acquired mineralocorticoid excess Katharina R. Beck, Alex Odermatt * Swiss Centre for Applied Human Toxicology and Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland ARTICLE INFO ABSTRACT Keywords: The syndromes of mineralocorticoid excess describe a heterogeneous group of clinical manifestations leading to Hypertension endocrine hypertension, typically either through direct activation of mineralocorticoid receptors or indirectly by Mineralocorticoid excess impaired pre-receptor enzymatic regulation or through disturbed renal sodium homeostasis. The phenotypes of Azole antifungal these disorders can be caused by inherited gene variants and somatic mutations or may be acquired upon ex­ Adverse drug reaction posures to exogenous substances. Regarding the latter, the symptoms of an acquired mineralocorticoid excess CYP11B 11β-hydroxysteroid dehydrogenase have been reported during treatment with azole antifungal drugs. The current review describes the occurrence of mineralocorticoid excess particularly during the therapy with posaconazole and itraconazole, addresses the underlying mechanisms as well as inter- and intra-individual differences, and proposes a therapeutic drug monitoring strategy for these two azole antifungals. Moreover, other therapeutically used azole antifungals and ongoing efforts to avoid adverse mineralocorticoid effects of azole compounds are shortly discussed. may often be unrecognized. The following sections cover the targets and mechanisms involved in SME, followed by a discussion of recent findings 1. Introduction on azole antifungals causing acquired SME. The management and prevention of hypertension represents an 2. Targets of mineralocorticoid excess and underlying important global health challenge.
    [Show full text]
  • Anti-Fungal Compounds: Emerging Environmental Contaminants
    Anti-fungal compounds: emerging environmental contaminants Azole fungicides are active ingredients in a range of pharmaceutical and personal care products, and are also used in agriculture. This study reviewed 23 September 2016 the sources, presence and risks of these compounds in the environment, finding Issue 471 evidence of toxic effects on aquatic organisms. The researchers provide directions Subscribe to free for future research and warn caution should be exercised until more toxicity data weekly News Alert becomes available. Source: Chen, Z. & Ying, G. Azole fungicides are used to treat fungal infections in agriculture and human (2015). Occurrence, fate and medicine. Usually administered in the form of tablets and ointments, azole fungicides can ecological risk of five typical also be found in common household products, from shampoo and soap to toothpaste and azole fungicides as therapeutic shower gel. Climbazole, which is used in anti-dandruff shampoos and anti-ageing creams, is and personal care products in reportedly used in Europe at a rate of 100–1 000 tonnes per year1. the environment: A review. Environment International, Over the past 10 years, these compounds have emerged as a new class of environmental 84: 142–153. DOI: 10.1016/ pollutants. After use, they are flushed into wastewater treatment plants (WWTPs) and j.envint.2015.07.022. released into rivers where they may have adverse effects on non-target organisms. They are mainly emitted via hospital and municipal wastewater treatment plants. Contact: [email protected], This study investigated the occurrence, life cycle in the environment and toxic effects of the [email protected] five most commonly used azole fungicides: climbazole, clotrimazole, ketoconazole, Read more about: miconazole and fluconazole (most of which are authorised in the EU for use in either human or veterinary medicines and none of which is approved as an active substance to be used in Chemicals, Risk plant-protection products).
    [Show full text]
  • Seborrheic Dermatitis and Its Relationship with Malassezia Spp
    REVIEW Seborrheic dermatitis and its relationship with Malassezia spp Manuel Alejandro Salamanca-Córdoba†,1,2, Carolina Alexandra Zambrano-Pérez2,3, Carlos Mejía-Arbeláez2,4, Adriana Motta5, Pedro Jiménez6, Silvia Restrepo-Restrepo7, Adriana Marcela Celis-Ramírez1,8* Abstract Seborrheic dermatitis (SD) is a chronic inflammatory disease that that is difficult to manage and with a high impact on the individual’s quality of life. Besides, it is a multifactorial entity that typically occurs as an inflammatory response toMalassezia species, along with specific triggers that contribute to its pathophysiology. Sin- ce the primary underlying pathogenic mechanisms include Malassezia proliferation and skin inflammation, the most common treatment includes topical antifungal keratolytics and anti-inflammatory agents. However, the consequences of eliminating the yeast population from the skin, the resistance profiles ofMalassezia spp. and the effectivity among different groups of medications are unknown. Thus, in this review, we summarize the current knowledge on the disease´s pathophysio- logy and the role of Malassezia sp. on it, as well as, the different antifungal treatment alternatives, including topical and oral treatment in the management of SD. Key words: seborrheic dermatitis, Malassezia, pathogenic role, treatment. Dermatitis seborreica y su relación con Malassezia spp Resumen La dermatitis seborreica (DS) es una enfermedad inflamatoria crónica, con un elevado impacto en la calidad de vida del individuo. Además, DS es una entidad multifactorial que ocurre como respuesta inflamatoria a las levaduras del género Malassezia spp., junto con factores desencadenantes que contribuyen a la fisio- patología de la enfermedad. Dado que el mecanismo patogénico principal involucra la proliferación e inflamación generada por Malassezia spp., el tratamiento más usado son los agentes tópicos antifúngicos y antiinflamatorios.
    [Show full text]
  • Clinical Evaluation of Herbal Active Enriched Shampoo in Anti Dandruff Treatment
    Theranostics of Respiratory L UPINE PUBLISHERS & Skin Diseases Open Access DOI: 10.32474/TRSD.2018.01.000105 ISSN: 2644-1306 Research Article Clinical Evaluation of Herbal Active Enriched Shampoo in Anti Dandruff Treatment Sudhir Sawarkar1*, Vinay Deshmukh2, Sankar Jayaganesh1 and Ovureddiar Perumal 1Dabur Research & Development, International Business Development, United Arab Emirates 2Sarkone Life sciences, United Arab Emirates Received: May 26, 2018; Published: June 07, 2018 *Corresponding author: Dr. Sudhir Sawarkar, Dabur Research & Development, International Business Development, Dubai, United Arab Emirates, P.O.Box. 6399 Abstract The human scalp is susceptible to microbial build-up if not thoroughly and frequently washed with the appropriate cleansing agents such as shampoos. Natural oils are presented in our scalp and it called as a sebum and it is a fuel/food for the dandruff-causing microbe. Malassezia feeds off these oils, breaking it down into by products, including oleic acid; formation of oleic acid is a starting/ kick point of dandruff. Approximately 50% people in the world sensitive to the oleic acid and affected by the dandruff. Overall clinical study results revealed that usage of tested anti-dandruff shampoo is effective and significantly reduce the dandruff fungi in Analogue Scale (VAS). The average response of Visual Analogue Scale for visit1 and visit 5 was 6.287 and 0.350 respectively. The scalp. Efficacy was analyzed with changes in the intensity of dandruff over 6 weeks from baseline to treatment visits using Visual average response/changes of Visual Analogue Scale score for Visit1 is 100.00 and Visit 2 having the score of 74.360; Visit 3 having the 47.924, Visit 4 having the score of 19.453 and Visit 5 was having the score of 5.567.
    [Show full text]